Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
Ovarian Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer focused on measuring biweekly schedule of PLD - Ovarian cancer - pegylated liposomal doxorubicin -quality of life - Toxic skin reactions
Eligibility Criteria
Inclusion Criteria: Patients ≥ 18 years of age recurrent ovarian, peritoneal, or tubal cancer and prior treatment with platinum- and paclitaxel were eligible to this trial. Eastern Cooperative Oncology Group (ECOG) performance status less than 3. renal function (serum creatinine 1.25 times the upper limit of normal, glomerular filtration rate greater than 60 ml/min) liver function (AST/ ALT three times the upper limit of normal, bilirubin concentrations 1.25 the upper limit of normal) bone marrow function (neutrophil count greater than 1.5 x 109/l, and a platelet count greater than 100 x 109/l). Exclusion Criteria: patients with more than 4 chemotherapies in medical history severe cardiac disease
Sites / Locations
Arms of the Study
Arm 1
Experimental
Caelyx